Search - tctmd.com

Displaying 341 - 360 of 499

Sort: Relevancy | Date

News Daily News

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Shelley Wood

January 18, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Yael L. Maxwell

December 22, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

L.A. McKeown

December 14, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Daily News

Societies Issue Recommendations for Operators, Institutions Offering LAA Closure Procedures

L.A. McKeown

December 10, 2015

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

Does the Watchman LAA Occluder Reduce Bleeding?

L.A. McKeown

November 25, 2015

News Opinion Editor's Corner

My Takeaways From AHA 2015

Shelley Wood

November 18, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Conference News AHA 2015

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

Yael L. Maxwell

November 09, 2015

News Daily News

NEJM Endorses Robert Califf for FDA Commissioner

L.A. McKeown

October 30, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

Advertisement

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Societies Issue Recommendations for Operators, Institutions Offering LAA Closure Procedures

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Does the Watchman LAA Occluder Reduce Bleeding?

My Takeaways From AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

NEJM Endorses Robert Califf for FDA Commissioner

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Discussion Highlights Merits, Limitations of Small Trials

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

Use of LAA Occlusion in Low-Risk Patients Debated

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content